Everolimus - Abbott

Drug Profile

Everolimus - Abbott

Alternative Names: Absorb; Affinitor; Affinitor Dispersible; Afinitor; Afinitor DISPERZ; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Synergy-everolimus-eluting-stent; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Amgen; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Genentech; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; resTORbio; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of Pittsburgh; University of Sydney; University of Texas M. D. Anderson Cancer Center; VU University Medical Center; Yale University
  • Class Antineoplastics; Macrolides; Polyenes
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Astrocytoma; Angiomyolipoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Partial epilepsies; Renal cell carcinoma; Renal transplant rejection
  • Phase III Autosomal dominant polycystic kidney disease; Hepatocellular carcinoma; Myocardial infarction
  • Phase II Brain metastases; Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Meningioma; Neurofibromatoses; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma; Respiratory tract infections; Sarcoma
  • Phase I/II Bladder cancer; Colorectal cancer; Oesophageal cancer
  • Phase I Solid tumours
  • No development reported Cervical cancer; Mantle-cell lymphoma; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Thyroid cancer; Tuberous sclerosis
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 01 Jun 2018 Novartis completes a phase II trial in Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT00827359)
  • 10 Apr 2018 Launched for Partial epilepsies (Adjunctive treatment, In adolescents, In children, In adults) in USA (PO)
  • 10 Apr 2018 Registered for Partial epilepsies (In adolescents, In children, In adults, Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top